VIDEO: Visual acuity in wet AMD maintained or improved after switch to brolucizumab

ByMathew W. MacCumber, MD, PhD

ByEamon N. Dreisbach

Fact checked byChristine Klimanskis, ELS

In this Healio Video Perspective, Mathew W. MacCumber, MD, PhD, discusses his poster presentation on brolucizumab treatment from the Retina Society meeting.

The real-world study found that more than 85% of eyes with neovascular age-related macular degeneration treated with brolucizumab after previous anti-VEGF treatment experienced stable or improved visual acuity at 12 months.

“I think this data is important because it will give retina specialists another agent that they can use in their armamentarium to treat neovascular age-related macular degeneration,” MacCumber said.

Published by:

Sources/Disclosures

Collapse

Source:

MacCumber MW, et al. Effectiveness and durability of brolucizumab treatment in real-world neovascular age-related macular degeneration (nAMD) patients in the U.S.: Findings from the American Academy of Ophthalmology IRIS Registry (Intelligence Research in Sight). Presented at: Retina Society meeting; Nov. 2-5, 2022; Pasadena, California.

Disclosures: MacCumber reports consulting for Alimera, Clearside Biomedical, Genentech, Novartis and Regeneron and receiving research grants from Alimera and Regenxbio.

OSN Instagram

Read more

VIDEO: Visual acuity in wet AMD maintained or improved after switch to brolucizumab

Related Content